Niva Bupa Q4 FY26 profit jumps 67%, stock up 10%

Stock jumps after results, then pares gains

Niva Bupa Health Insurance Company shares rallied after the insurer reported its March-quarter (Q4FY26) results. The stock gained 10.3% on BSE to an intra-day high of ₹89.72 per share. By 9:52 AM, the rally cooled, with the stock up 4.58% at ₹84.99 per share. The broader market was weaker, with the BSE Sensex down 1.38% at 76,260.36. The company announced its Q4FY26 numbers on Friday after market hours, giving the market its first full read-through of the quarter.

Q4FY26: profit rises sharply on higher premium and income

For Q4FY26, Niva Bupa reported a net profit of ₹345.13 crore, compared with ₹206.08 crore in Q4FY25, a year-on-year increase of 67.4%. Premium earned rose to ₹1,971.95 crore from ₹1,527.42 crore in the year-ago quarter. Total income for the quarter stood at ₹2,077.66 crore, up from ₹1,564.73 crore a year ago. In a separate regulatory update cited in the same coverage, the company also disclosed that total expenses rose to ₹1,795 crore from ₹1,470 crore in the corresponding quarter last year.

Operating profitability improved in Q4

The quarter also showed a stronger operating profile versus the year-ago period. Operating margin for Q4FY26 was reported at 18.52% versus 16.41% in Q4FY25. The report also highlighted that operating profit before depreciation, interest, and tax (excluding other income) rose to ₹365.23 crore in Q4FY26 from a loss of ₹94.21 crore in Q3FY26, reflecting a sharp sequential swing. A separate data point in the same coverage referenced return on equity at 5.00% (average ROE), while the earnings call commentary cited a double-digit return on net worth for the full year.

Full-year GWP and retail segment share

For FY26, Niva Bupa reported gross written premium (GWP) of ₹8,586 crore (with 1/n) and ₹9,433 crore (without 1/n), with year-on-year growth stated at 27%. For Q4FY26, GWP was ₹2,880 crore (with 1/n) and ₹3,123 crore (without 1/n), with growth of 39% mentioned for the “with 1/n” figure. In another filing-based summary included in the provided text, gross written premium for the quarter was also compared with ₹2,079 crore in the same period a year ago.

Niva Bupa said it strengthened its position in the retail health segment, with retail market share improving to 10.1% at the close of FY26, a 76 basis point increase over FY25. The earnings call transcript added that retail market share in Q4 specifically moved to 10.4% from 9%.

Claims, customer metrics, and service indicators

Service metrics were also highlighted alongside financial growth. The company reported a claim settlement ratio of 94.4% for FY26, improving by 205 basis points over the previous year. Net promoter score (NPS) improved to 60 at the end of FY26 from 55 in FY25, indicating better customer advocacy scores as tracked by the company.

FY26 volatility: three loss quarters, then a Q4 turnaround

Alongside the strong Q4 headline numbers, the coverage flagged significant earnings volatility through FY26. It described consecutive quarterly losses in Q1, Q2, and Q3, followed by a sharp return to profit in Q4. The quarter-by-quarter table in the provided text shows profits in Mar’25 and Mar’26, with losses in Jun’25, Sep’25, and Dec’25. It also stated that the company posted consecutive losses totalling ₹214.35 crore across Q1, Q2, and Q3 of FY26 before the Q4 recovery.

Solvency ratio and FY26 financial ratios from the earnings call

The filings-based coverage said the solvency ratio declined to 2.49 as on March 31, 2026 from 3.03 at the end of the fourth quarter of the previous fiscal year. The earnings call added several FY26 indicators: analyzed investment yield of 7.2% with assets under management (AUM) of ₹9,670 crore, and a solvency ratio of 2.49 as of March 31, 2026. It also cited an improvement in the combined ratio under IFRS by 160 basis points to 101.4% for FY26, and an expense of management ratio improving to 33.7% from 39.2% last year.

Leadership update: deputy CEO appointment

In the same set of disclosures included in the text, the board approved the elevation of Ankur Kharbanda, currently executive director and chief business officer, to executive director and deputy chief executive officer. The appointment was approved effective May 8, based on the recommendation of the nomination and remuneration committee.

Stock performance context: mixed longer-term, stronger recent momentum

The report noted that the stock underperformed the broader insurance sector over the past year, declining 6.99% while the insurance sector rallied 17.75%, implying an underperformance of 24.74 percentage points. At the same time, it cited improved recent momentum, with the stock gaining 10.83% over the past month and 7.64% year-to-date. Over the same periods, the Sensex was noted as down 0.30% and 9.26%, respectively.

Key numbers snapshot

Why this quarter matters for investors

The March-quarter print combined strong growth in premium earned and total income with a sharp improvement in profitability. But the same dataset also shows that profitability in FY26 was uneven, with losses through the middle of the year before the Q4 rebound. For insurance businesses, the sustainability of margins, combined ratio discipline, and solvency headroom are closely watched, and the disclosed solvency ratio movement to 2.49 becomes an important part of the conversation. Separately, the company’s reported improvement in retail market share, claim settlement ratio, and NPS suggests the insurer is trying to pair growth with service performance.

What to watch next

Investors will track how the insurer performs after a sharp Q4 swing, particularly whether profitability stabilises after the quarterly volatility highlighted in FY26. Disclosures around combined ratio, expense management, and solvency levels will remain key reference points in upcoming quarters. The market will also watch execution under the updated leadership structure following the deputy CEO appointment effective May 8.